The molecular basis of paroxysmal nocturnal hemoglobinuria

Haematologica

Volumn 85, Issue 1, 2000, Pages 82-87

  Rosti, Vittorio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Amphotericin; Antifungal agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Liposome; Mycoses

Indexed keywords

CELL SURFACE PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL;

APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CELL PROLIFERATION; CYTOPENIA; GENE INACTIVATION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HEMOLYSIS; HUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; THROMBOSIS;

GLYCOSYLPHOSPHATIDYLINOSITOLS; HEMATOPOIETIC STEM CELLS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MEMBRANE PROTEINS; MUTATION;

EID: 0033974579     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Hillmen P, Lewis MS, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253-8.
2. Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal hemoglobinuria: long term follow up and prognostic factors. Lancet 1996; 348:573-7.
3. Rosse WF, Dacie JV. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest 1966; 45: 736-48.
4. Davits MA, Low MG, Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). J Exp Med 1986; 163:1150-61.
5. Dameshek W. Riddle: what do aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH) and "hypoplastic" leukemia have in common? Blood 1967; 30:251-4.
6. Lewis SM, Dacie JV. The aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol 1967; 13:236-51.
7. Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 1996; 87: 5332-40.
8. Ferguson MAJ. Glycosyl-phosphatidylinositol membrane anchor: the tale of a tail. Biochem Soc Transactions 1992; 20:243-56.
9. Caras IW, Davitz MA, Rhee L, Wendel G, Martin DW, Nussenzweig V. Cloning of decay accelerating factor suggests novel use of splicing to generate two proteins. Nature 1987; 325:545-9.
10. Ravetch JV, Perussia B. Alternative membrane forms of FcγR III (CD16) on human natural killer cells and neutrophils. Cell type specific expression of two genes that differ in single nucleotide substitution. J Exp Med 1989; 170:481-90.
11. Cross AGM. Cellular and genetic aspects of antigenic variation in trypanosomes. Ann Rev Immunol 1990; 8: 83-110.
12. Anderson RGW, Kamen BA, Rotenberg KG, et al. Potocytosis: sequestration and transport of small molecules by caveolae. Science 1992; 255:410-1.
13. Robinson PJ. Phosphatodylinositol membrane anchors and T-cell activation. Immunol Today 1991; 12:35-41.
14. Tarutani M, Itami S, Okabe M, et al. Tissue specific knock out of the mouse PIG-A gene reveals important roles for GPI-anchored proteins in skin development. Proc Natl Acad Sci USA 1997; 94:7400-5.
15. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology and function. Ann Rev Immunol 1989; 7:35-58.
16. Meri S, Morgan B, Davies A, et al. Human protectin (CD59) an 18,000-20,000 MW complement lysis restriction factor, inhibits C5b-8 catalysed insertion into lipid bilayers. Immunology 1990; 71:1-9.
17. Yamashima M, Ueda E, Kinoshita T, et al. Inherited complement deficiency of 20 kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990; 323: 1184-9.
18. Motoyama N, Okada N, Yamashima M, Okada H. Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF (CD59) gene. Eur J Immunol 1992; 22:2669-73.
19. Merry AH, Rawlinson M, Uchikawa M, Dho MR, Sim RB. Studies on the sensitivity to complement mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). Br J Haematol 1989; 73:248-53.
20. Tate CG, Uchikawa M, Tanner MJA, et al. Studies on the defect which causes absence of decay accelerating factor from the peripheral blood cells of an individual with the Inab phenotype. Biochem J 1989; 261:489-93.
21. Hillmen P, Hadzic D, O'Connor SJM, Mowat A. Hepatic vein thrombosis in a patient with the Inab phenotype: is deficiency of DAF important in the development of thrombosis in PNH? [abstract]. Blood 1995; 86(Suppl 1): 514a.
22. Armstrong C, Schubert J, Ueda E, et al. Affected paroxysmal nocturnal T lymphocytes harbour a common defect in assembly of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-1-murine lymphoma mutants. J Biol Chem 1992; 267: 25347-51.
23. Hillmen P, Bessler M, Mason PJ, et al. Specific defect in N-acetylglucosamine incorporation in the GPI anchor synthetic pathway in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1993; 90: 5272-6.
24. Miyata T, Takeda J, Iida J, et al. The cloning of PIG-A, a component in the early step of the GPI-anchor biosynthesis. Science 1993; 259:1318-20.
25. Takeda J, Miyata T, Kawagoe K, et al. Deficincy of the GPI-anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73:703-11.
26. Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal hemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994; 13:110-7.
27. Miyata T, Yamada N, Iida Y, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 1994; 330: 249-55.
28. Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 1995; 86: 3277-86.
29. Nafa K, Mason P, Hillmen P, Bessler M. Mutations in the PIG-A gene causing paroxysmal nocturnal hemoglobinuria (PNH) are mainly of the frameshift type. Blood 1995; 86:4650-5.
30. Bessler M, Hillmen P, Longo L, et al. Genomic organization of the X-linked gene (PIG-A) that is mutated in paroxysmal nocturnal hemoglobinuria and of a related pseudogene mapped to 12q21. Hum Mol Genet 1994; 3:751-7.
31. Iida Y, Takeda J, Miyata T, et al. Characterization of genomic PIG-A gene: a gene for glycosylphosphatidyl-inositol-anchor biosynthesis and paroxysmal nocturnal hemoglobinuria. Blood 1994; 83:3126-31.
32. Watanabe R, Kinoshita T, Masaki R, et al. PIG-A and PIG-H, which participate in glycosylphosphatidyl-inositol anchor biosynthesis, form a protein complex in the endoplasmic reticulum. J Biol Chem 1996; 271: 26868-75.
33. Ware RE, Rosse WF, Howard TA. Mutations within the PIG-A gene in patients with paroxysmal nocturnal hemoglobinuria. Blood 1994; 83: 2418-22.
34. Bessler M, Mason PJ, Hillmen P, et al. Mutations in the PIG-A gene causing partial deficiency of GPI-linked surface proteins (PNH II) in patients with paroxysmal nocturnal hemoglobinuria. Br J Haematol 1994; 87: 863-6.
35. Bessler M, Mason PJ, Hillmen P, Luzzatto L. Somatic mutations and cellular selection in paroxysmal nocturnal hemoglobinuria. Lancet 1994; 343:951-3.
36. Pramoonjago P, Wanachiwanawin W, Chinprasertsack S, Pattanapanyasat K, Takeda J, Kinoshita T. Somatic mutations of PIG-A in Thai patients with paroxysmal nocturnal hemoglobinuria. Blood 1995; 86:1736-9.
37. Rotoli B, Boccuni P. The PIG-A gene somatic mutation responsible for paroxysmal nocturnal hemoglobinuria. Haematologica 1995; 80:539-45.
38. Yamada N, Miyata T, Maeda K, et al. Somatic mutations in the PIG-A gene found in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood 1995; 85:885-92.
39. Kinoshita T, Inoue N, Takeda J. Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria. Adv Immunol 1995; 60:57-103.
40. Nafa K, Bessler M, Castro-Malaspina H, Jhanwar S, Luzzatto L. The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. Blood Cells Mol Dis 1998; 24:370-84.
41. Endo M, Ware RE, Vreeke TM, et al. Identification and characterization of an inherited mutation of PIG-A in a patient with paroxysmal nocturnal hemoglobinuria. Br J Haematol 1996; 95:590-3.
42. Oni SB, Osunkoya BO, Luzzatto L. Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood 1970; 36:145-52.
43. Rotoli B, Robledo R, Scarpato N, Luzzatto L. Two populations of erythroid cell progenitors in paroxysmal nocturnal hemoglobinuria. Blood 1984; 64:847-51.
44. Endo M, Ware RE, Vreeke TM, et al. Molecular basis of the heterogeneity of expression of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglobinuria. Blood 1996; 87:2553-7.
45. Nishimura J, Inoue N, Wada H, et al. A patient with paroxysmal nocturnal hemoglobinuria bearing four independent PIG-A mutant clones. Blood 1997; 89: 3470-6.
46. Kawagoe K, Kitamura D, Okabe M, et al. Glycosyl-phosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood 1996; 87: 3600-6.
47. Rosti V, Tremml G, Soares V, Pandolfi PP, Luzzatto L, Bessler M. Murine embryonic stem cells without PIG-A gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. J Clin Invest 1997; 100:1028-36.
48. Tremml G, Dominguez C, Rosti V, et al. Increased sensitivity to complement and a decreased red cell life span in mice mosaic for a non-functional PIG-Agene. Blood 1999; 94:2945-54.
49. Rotoli B, Luzzatto L. Paroxysmal nocturnal hemoglobinuria. Bailliere's Clin Haematol 1989; 2:113-38.
50. Young N. The problem of clonality in aplastic anemia: Dr. Dameshek's riddle, restated. Blood 1992; 79: 1385-90.
51. Rotoli B, Luzzatto L. Decreased number of circulating BFU-Es in paroxysmal nocturnal hemoglobinuria. Blood 1982; 60:157-9.
52. Maciejewski J, Sloand E, Sato T, et al. Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective defect in the glycosyl phosphatidylinositol-anchored protein deficient clone. Blood 1997; 89:1173-81.
53. Iwamoto N, Kawaguchi T, Horikawa K, et al. Preferential hematopoieis by paroxysmal nocturnal hemoglobinuria clone engrafted in SCID mice. Blood 1996; 87:4944-8.
54. Hertenstein B, Wagner B, Bunjes D, et al. Emergence of CD52-, phosphatidyl-inositol-glycan-anchor-deficient T lymphocytes after in vivo application of Campath 1H for refractory B-cell non-Hodgkin's lymphoma. Blood 1995; 86:1487-92.
55. Brett SJ, Baxter G, Cooper H, et al. Emergence of CD52-glycosyl phosphatidyl inositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath 1H treatment. Int Immunol 1996; 8:325-34.
56. Taylor VC, Sims M, Brett S, Field MC. Antibody selection against CD52 produces a paroxysmal nocturnal hemoglobinuria phenotype in human lymphocytes by a novel mechanism. Biochem J 1997; 322:919-25.
57. Rawstron AC, Rollinson SJ, Richards S, et al. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol 1999; 107:148-53.
58. Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA 1999; 96:5209-14.
59. Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 1996; 3:101-10.
60. Luzzatto L, Bessler M, Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: A blessing in disguise? Cell 1997; 88:1-4.
61. Bessler M, Hillmen P. Somatic mutations and cellular selection in the pathogenesis and control of paroxysmal nocturnal hemoglobinuria. Semin Hematol 1998; 35:149-67.